Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Boobalan Pachaiyappan
ROTH
Boobalan Pachaiyappan
Roth MKM
Wall Street Analyst
★★☆☆☆
#2292
on 13Foresight · ranked by our own returns
33%
Success Rate
+14.1%
Average Return
4 of 12 calls profitable · -1.3% vs benchmark
📈 Across the calls we could measure, roughly 33% of Boobalan Pachaiyappan's ratings turned a profit when each position was held for 2 year — averaging +14.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

97 Buy 4 Hold 0 Sell
Boobalan's Stock Coverage 22 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return
CRVO
CervoMed
 Jun 12, 2026 BUY Strong Buy
+328.2% avg upside
9 analysts
$9.00
136.23% Upside
 ·
NRSN
Neurosense Therapeutics Ltd.
 Jun 10, 2026 BUY Strong Buy
+1057.8% avg upside
5 analysts
$3.00
325.48% Upside
 ·
COYA
Coya Therapeutics, Inc.
 Jun 05, 2026 BUY Strong Buy
+219.6% avg upside
7 analysts
$12.00
138.51% Upside
 +0.0%
CING
Cingulate Inc
 Jun 04, 2026 BUY Strong Buy
+355.6% avg upside
5 analysts
$10.00
95.34% Upside
 ·
TRDA
Entrada Therapeutics Inc
 Jun 03, 2026 BUY Strong Buy
+210.2% avg upside
10 analysts
$10.00
46.79% Upside
 -2.7%
PYPD
PolyPid
 Jun 02, 2026 BUY Strong Buy
+260.6% avg upside
7 analysts
$9.00
97.47% Upside
 ·
CAPR
Capricor Therapeutics
 May 29, 2026 BUY Strong Buy
+70.5% avg upside
12 analysts
$38.00
35.98% Upside
 ·
GANX
Gain Therapeutics
 May 27, 2026 BUY Strong Buy
+337.1% avg upside
9 analysts
$8.00
349.39% Upside
 ·
LBRX
LB Pharmaceuticals, Inc.
 May 18, 2026 BUY Strong Buy
+51.0% avg upside
7 analysts
$37.00
23.19% Upside
 +0.5%
LGVN
Longeveron
 May 15, 2026 BUY Strong Buy
+5293.1% avg upside
4 analysts
$3.00
257.23% Upside
 ·
OVID
Ovid Therapeutics
 May 14, 2026 BUY Strong Buy
+98.5% avg upside
17 analysts
$7.00
189.28% Upside
 -6.1%
IMUX
Immunic
 May 14, 2026 BUY Strong Buy
+166.9% avg upside
21 analysts
$19.00
33.84% Upside
 +9.5%
RVPH
Reviva Pharmaceuticals Holdings
 Apr 01, 2026 BUY Strong Buy
+7391.6% avg upside
9 analysts
$1.00
71.66% Upside
 -11.7%
PXMD
PaxMedica, Inc.
 May 20, 2024 HOLD Hold
1 analyst
 — ·
ANEB
Anebulo Pharmaceuticals
 May 20, 2024 HOLD Buy
+661.0% avg upside
5 analysts
 — -78.6%
SPRB
Spruce Biosciences
 May 20, 2024 HOLD Strong Buy
+98.5% avg upside
14 analysts
 — -98.8%
BWAY
Brainsway
 May 20, 2024 HOLD Strong Buy
-9.1% avg upside
9 analysts
 — +456.6%
RKTO
Rocket One
 May 20, 2024 HOLD Strong Buy
+900.2% avg upside
8 analysts
 — ·
TSE:CSCI
COSCIENS Biopharma
 May 20, 2024 HOLD Strong Buy
+435.6% avg upside
8 analysts
 — ·
ENSC
Ensysce Biosciences
 May 20, 2024 HOLD Buy
+5459.7% avg upside
3 analysts
 — -97.2%
DMRA
Damora Therapeutics
 Oct 24, 2023 HOLD Strong Buy
+26.5% avg upside
19 analysts
 — ·
GRTX
Galera Therapeutics
 Sep 19, 2023 HOLD Buy
+6797.5% avg upside
7 analysts
$0.30
252.96% Upside
 ·
🔒 17 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Boobalan Pachaiyappan — Frequently Asked Questions
How accurate are Boobalan Pachaiyappan's stock ratings?
Based on the calls 13Foresight could measure, about 33% of Boobalan's ratings were profitable over a one-year hold, with an average return of -11.8% per rating, or -17.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Boobalan ranked on 13Foresight?
Boobalan Pachaiyappan is currently ranked #2292 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Boobalan cover?
Boobalan most recently has ratings on CRVO, NRSN, COYA, CING, TRDA, PYPD, CAPR, GANX, LBRX, LGVN, OVID, IMUX and 10 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.